ISSN 1671-5411 CN 11-5329/R

Dear Colleagues,

Journal of Geriatric Cardiology (J Geriatr Cardiol, JGC) will launch a new website and adopt ScholarOne ManuscriptsTM system to manage the submission and peer review process from November 1, 2020. To review and check the status of your manuscripts submitted before November 2020, please visit...

more

Volume 17 Issue 11
Dec.  2020
Turn off MathJax
Article Contents
Sheng-Li DU, Xin-Chun YANG, Jiu-Chang ZHONG, Le-Feng WANG, Yi-Fan FAN. Plasma levels of Elabela are associated with coronary angiographic severity in patients with acute coronary syndrome. J Geriatr Cardiol 2020; 17(11): 674-679. doi: 10.11909/j.issn.1671-5411.2020.11.004
Citation: Sheng-Li DU, Xin-Chun YANG, Jiu-Chang ZHONG, Le-Feng WANG, Yi-Fan FAN. Plasma levels of Elabela are associated with coronary angiographic severity in patients with acute coronary syndrome. J Geriatr Cardiol 2020; 17(11): 674-679. doi: 10.11909/j.issn.1671-5411.2020.11.004

Plasma levels of Elabela are associated with coronary angiographic severity in patients with acute coronary syndrome

doi: 10.11909/j.issn.1671-5411.2020.11.004
More Information
  • Corresponding author:

    Jiu-Chang ZHONG, Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100020, China. E-mails: jiuchangzhong@aliyun.com (ZHONG JC)

    Le-Feng WANG, Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100020, China. E-mails: wlf20182021@163.com (WANG LF)

    Yi-Fan FAN, Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100020, China. E-mails: dryifan@163.com (FAN YF)

  • Received Date: 2020-07-01
  • Accepted Date: 2020-10-19
  • Rev Recd Date: 2020-10-19
  • Available Online: 2020-11-28
  • Publish Date: 2020-11-28
  •  Background Elabela (ELA) was newly discovered as a novel endogenous ligand of the apelin receptor (APJ) which has demonstrated to be crucial for cardiovascular disease such as myocardial infarction, hypertension and heart failure. Previous experiments have revealed that ELA reduced arterial pressure and exerted positive inotropic effects on the heart. However, the role of plasma ELA levels in patients with acute coronary syndrome (ACS) and its relationship with severity of coronary arteries have not been investigated. Methods Two hundred and one subjects who were hospitalized for chest pain and underwent coronary angiography were recruited in this study. One hundred and seventy five patients were diagnosed with ACS and twenty-six subjects with negative coronary angiography were included in the control group. Plasma ELA levels, routine blood test, blood lipid, liver and kidney functions were measured. The number of coronary arteries and SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score of coronary lesions were used to evaluate the extent of coronary artery stenosis. Results ELA in patients with ACS was significantly higher than that in the control group (P < 0.01). There was no significant difference in plasma ELA levels among patients with single-, double- and triple-vessel diseases. However, in the generalized additive model (GAM), there was a threshold nonlinear correlation between the ELA levels and Syntax I score (P < 0.001). Plasma ELA levels were positively correlated with the Syntax I score when the ELA levels ranged from 63.47 to 85.49 ng/mL. There was no significant association between the plasma ELA levels and the extent of coronary artery stenosis when the ELA levels were less than 63.47 ng/mL or higher than 85.49 ng/mL. Conclusion The present study demonstrates for the first time that plasma ELA levels are increased in patients with ACS. The rise in endogenous ELA levels was associated with severity of coronary stenosis and may be involved in the pathogenesis of ACS.
  • Telephone: +86-10-85231170 Fax: +86-10-85231178
  • loading
  • [1]
    De Mota N, Reaux-Le Goazigo A, El Messari S, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A 2004; 101: 10464-10469. doi: 10.1073/pnas.0403518101
    [2]
    Yang P, Read C, Kuc RE, et al. Elabela/Toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation 2017; 135: 1160-1173. doi: 10.1161/CIRCULATIONAHA.116.023218
    [3]
    Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci 2015; 36: 560-567. doi: 10.1016/j.tips.2015.06.002
    [4]
    Ma Z, Song JJ, Martin S, Yang XC, Zhong JC. The Elabela- APJ axis: a promising therapeutic target for heart failure. Heart Fail Rev 2020; 1-10. doi: 10.1007/s10741-020-09957-5
    [5]
    Sharma B, Ho L, Ford GH, et al. Alternative progenitor cells compensate to rebuild the coronary vasculature in Elabela- and APJ-deficient hearts. Dev Cell 2017; 42: 655-666 e653. doi: 10.1016/j.devcel.2017.08.008
    [6]
    Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell 2013; 27: 672-680. doi: 10.1016/j.devcel.2013.11.002
    [7]
    Wang Z, Yu D, Wang M, et al. Elabela-apelin receptor signaling pathway is functional in mammalian systems. Sci Rep 2015; 5: 8170. doi: 10.1038/srep08170
    [8]
    Zhang Y, Wang Y, Lou Y, et al. Elabela, a newly discovered APJ ligand: Similarities and differences with Apelin. Peptides 2018; 109: 23-32. doi: 10.1016/j.peptides.2018.09.006
    [9]
    Murza A, Sainsily X, Coquerel D, et al. Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions. J Med Chem 2016; 59: 2962-2972. doi: 10.1021/acs.jmedchem.5b01549
    [10]
    Helker CSM, Schuermann A, Pollmann C, et al. The hormonal peptide Elabela guides angioblasts to the midline during vasculogenesis. eLife 2015; 4: e06726. doi: 10.7554/eLife.06726
    [11]
    Wang Z, Yu DZ, Wang MQ, et al. Elabela-Apelin Receptor Signaling Pathway is Functional in Mammalian Systems. Sci Rep 2015; 5: 8170. doi: 10.1038/srep08170
    [12]
    Li Y, Yang X, Ouyang S, et al. Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function: A preliminary study. Clin Exp Hypertens 2020; 42: 239-243. doi: 10.1080/10641963.2019.1619756
    [13]
    Xu C, Wang F, Chen Y, et al. ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury. Am J Physiol Renal Physiol 2020; 318: F1122-F1135. doi: 10.1152/ajprenal.00606.2019
    [14]
    Yu P, Ma S, Dai X, Cao F. Elabela alleviates myocardial ischemia reperfusion-induced apoptosis, fibrosis and mitochondrial dysfunction through PI3K/AKT signaling. Am J Transl Res 2020; 12: 4467-4477. http://www.researchgate.net/publication/344232113_Elabela_alleviates_myocardial_ischemia_reperfusion-induced_apoptosis_fibrosis_and_mitochondrial_dysfunction_through_PI3KAKT_signaling
    [15]
    Xi Y, Yu D, Yang R, et al. Recombinant Fc-Elabela fusion protein has extended plasma half-life andmitigates post-infarct heart dysfunction in rats. Int J Cardiol 2019; 292: 180-187. doi: 10.1016/j.ijcard.2019.04.089
    [16]
    Perjes A, Kilpio T, Ulvila J, et al. Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. Basic Res Cardiol 2016; 111: 2. doi: 10.1007/s00395-015-0521-6
    [17]
    Sato T, Sato C, Kadowaki A, et al. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin Ⅱ-induced cardiac damage. Cardiovasc Res 2017; 113: 760-769. doi: 10.1093/cvr/cvx061
    [18]
    Donmez Y, Acele A. Increased Elabela levels in the acute ST segment elevation myocardial infarction patients. Medicine (Baltimore) 2019; 98: e17645. doi: 10.1097/MD.0000000000017645
    [19]
    Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 2020; 141: e139-e596.
    [20]
    Mastenbroek TG, van Geffen JP, Heemskerk JW, Cosemans JM. Acute and persistent platelet and coagulant activities in atherothrombosis. J Thromb Haemost 2015; 13 Suppl 1: S272-S280. http://smartsearch.nstl.gov.cn/paper_detail.html?id=9d1ca025bab208f92d52b9d2b79fcdeb
    [21]
    Liu XY, Lu Q, Ouyang XP, et al. Apelin-13 increases expression of ATP-binding cassette transporter A1 via activating protein kinase C alpha signaling in THP-1 macrophage-derived foam cells. Atherosclerosis 2013; 226: 398-407. doi: 10.1016/j.atherosclerosis.2012.12.002
    [22]
    Fraga-Silva RA, Seeman H, Montecucco F, et al. Apelin-13 treatment enhances the stability of atherosclerotic plaques. Eur J Clin Invest 2018; 48: e12891. doi: 10.1111/eci.12891
    [23]
    Akboga MK, Akyel A, Sahinarslan A, et al. Relationship between plasma apelin level and coronary collateral circulation. Atherosclerosis 2014; 235: 289-294. http://www.ncbi.nlm.nih.gov/pubmed/24905139
    [24]
    Guo YY, Li T, Liu H, et al. Circulating levels of Elabela and Apelin in the second and third trimesters of pregnancies with gestational diabetes mellitus. Gynecol Endocrinol 2020; 36: 890-894. doi: 10.1080/09513590.2020.1739264
    [25]
    Aydin S, Kuloglu T, Aydin Y, et al. Effects of iloprost and sildenafil treatment on elabela, apelin-13, nitric oxide, and total antioxidant and total oxidant status in experimental enzyme-positive acute coronary syndrome in rats. Biotech Histochem 2020; 95: 145-151. doi: 10.1080/10520295.2019.1653497
    [26]
    Wang Y. Recombinant Elabela-Fc fusion protein has extended plasma half-life and mitigates post-infarct heart dysfunction in rats. Int J Cardiol 2020; 300: 217-218. doi: 10.1016/j.ijcard.2019.06.043
    [27]
    Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang Ⅱ effects in mouse models of atherosclerosis. J Clin Invest 2008; 118: 3343-3354. http://pubmedcentralcanada.ca/pmcc/articles/PMC2525695/
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Article Metrics

    Article views (114) PDF downloads(12) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return